Ebola, a decades-old viral disease, is now curable with the latest medicines. Yes, two new Ebola drugs have revealed effective results. Now health officials are offering those treatments to all patients in the DRC (Democratic Republic of Congo). In the past few decades, the virus has ended the lives of thousands of people across Africa. The ongoing Ebola epidemic, which started in August 2018, is the second most fatal outbreak in the DRC. But this time, scientists seem to be one step closer to an Ebola drug. During a clinical trial, a set of treatment has revealed notable assurance at curing Ebola.
A team of researchers has explored four innovative drugs as probable cures for the fatal virus infection. Among those drugs, they have discovered two curative new medicines from the NIH (National Institutes of Health) and Regeneron Pharmaceuticals. Scientists claim the two experimental drugs can assist recover the survival of Ebola-affected people. Although, the discovery has raised survival rates for Ebola-affected people between 89 to 94%. The team had started the randomized trial in November. During the analysis, they have compared four drugs offered in four different towns to all patients in the DRC. After getting effective outcomes from two of the four treatments, the scientists have decided to stop the trial.
Jean-Jacques Muyembe, the Director of DRC’s INRB (Institut National de Recherche Biomedicale), said they had taken a new step. The executive noted, now onwards they will not any more call Ebola as a non-curable disease. Muyembe told in the future the discovery would assist in saving thousands of lives. Reportedly, primary results have shown that 499 patients who have gained the two more powerful drugs had a greater chance of survival. In this case, REGN-EB3, one of the effective drug, has revealed a mortality rate of around 29%. Besides, mAb114, the second effective treatment, has shown 34%. On the other hand, the remaining two drugs, ZMapp and Remdesivir, have revealed higher mortality rates, i.e., 49% and 53%. Anthony Fauci is the director of NAID and one of the scientists leading the clinical trial. According to Anthony, there is a fall in mortality rate after using the two more potent drugs.